Maria Kondratyev, CEO & Co-Founder of Aeterna Therapeutics

Welcome to Partnology’s Biotech Leader Spotlight Series, where we highlight the remarkable accomplishments and visionary leadership of biotech industry pioneers. This series is about showcasing the groundbreaking strides made by exceptional leaders who have transformed scientific possibilities into tangible realities. Through insightful interviews, we invite you to join us in following the inspiring journeys of these executives who continue to shape the landscape of the biotech industry. This week we are recognizing:

Maria Kondratyev is Co-Founder and CEO of Aeterna Therapeutics, a pre-clinical biopharmaceutical company that develops proprietary monoclonal antibodies for the treatment of metabolic disorders. Maria has distinguished expertise in biomedical research, drug discovery and business development and holds a Ph.D degree in Biochemistry from McMaster University, and an MBA in Management and Entrepreneurship from Smith’s School of Business. Her scientific career is highlighted by multiple patents, awards, and numerous publications in prestigious journals. Maria has over 20 years of experience leading diverse research projects, managing teams and overseeing activities from early discovery to target validation. In her last role as an Entrepreneur in Residence at the University Health Network, Maria led fundraising efforts, engaged with scientific founders, and has been establishing collaborations and partnerships within academia and industry.

You spent more than two decades in biomedical research and drug discovery before founding Aeterna Therapeutics in 2024. What inspired you to make the leap into entrepreneurship, and what unmet need did you see that convinced you it was time to build your own company?

I’ve been a scientist my entire life. I come from a family of scientists and cancer researchers, and I’ve always had a passion for basic research. But at some point, I began to feel frustrated by the disconnect between scientific innovation and its impact on patients. In cancer research, for example, there are so many brilliant minds dedicating decades to groundbreaking discoveries, supported by incredible advances in technology. Yet, many patients still rely on chemotherapy and radiation as their primary treatment options.

I wanted to help change that. I wanted to do more than publish research in prestigious journals or contribute knowledge for future generations. I wanted my work to have a more immediate, tangible impact on patients’ lives. To me, there was a clear unmet need to bridge the gap between basic science and clinical application through more translational research—research that could deliver meaningful, measurable improvements in patient outcomes.

For those unfamiliar with Aeterna Therapeutics, can you walk us through the company’s scientific platform, the underlying biology, and what makes your approach different from existing therapeutic strategies?

Our approach is completely novel. I like to describe it as simple and elegant. We’re using antibodies in a way they haven’t been used before. Traditionally, antibodies are used to antagonize or block signaling pathways, or to eliminate specific targets. Instead, we’re leveraging one of their most remarkable properties: their exceptionally long lifespan. Antibodies are among the longest-lived molecules in the body, which is why we call ours “Eternabodies,” inspired by the word eternity.

What’s particularly interesting is that scientists have known for some time that when a long-lived antibody binds to a short-lived target, it can effectively extend that target’s lifespan. However, this mechanism hasn’t traditionally been explored as a therapeutic strategy.

There are numerous diseases where extending the lifespan of naturally occurring, short-lived molecules could have significant therapeutic benefits, including oncology, metabolic disorders, and growth deficiencies. Pharmaceutical companies have spent years trying to achieve this by chemically modifying these molecules or attaching various components to extend their half-lives. Unfortunately, these approaches can create complex, Frankenstein-like molecules that are difficult to manufacture and don’t always function as intended.

Our approach is much simpler. We generate non-neutralizing antibodies that bind to these naturally occurring molecules without interfering with their biological activity. These antibodies can potentially be administered once a month, offering a highly convenient treatment regimen. Once administered, they find the molecules naturally produced by the body and help them remain in circulation for approximately three weeks, similar to the lifespan of the antibodies themselves.

That’s the foundation of our platform, and we’re exploring its potential across several disease indications where extending the activity of these naturally occurring molecules could meaningfully improve patient outcomes.

What have been some of the most exciting scientific discoveries or milestones at Aeterna so far, and what upcoming inflection points do you believe will be most important in demonstrating the platform’s potential?

Our first program focuses on growth hormone deficiency in children. Children with growth hormone deficiency don’t produce enough growth hormone to support normal growth and development. In some cases, there is no identifiable genetic cause; their bodies simply don’t produce enough of the hormone. Fortunately, there is a relatively straightforward treatment: injections of laboratory-produced growth hormone, which can help these children resume normal growth and development.

The challenge is that growth hormone has an extremely short half-life of approximately 15 minutes. As a result, many of these children require daily injections throughout their childhood. That’s an enormous burden, both physically and emotionally. The injections can be painful, and the daily treatment schedule makes everyday activities, including travel, much more complicated. For some families, the burden becomes so overwhelming that they eventually discontinue treatment.

That’s where our Eternabody technology comes in. We’ve developed an antibody that binds to human growth hormone without interfering with its biological activity. Rather than relying on daily injections of laboratory-produced growth hormone, our goal is to administer an antibody that binds to the growth hormone these children naturally produce. Although they don’t produce enough to support normal growth, they still produce some. By extending the hormone’s lifespan, we hope to allow it to accumulate in the body and maintain therapeutic levels for much longer.

Our vision is to replace daily injections with a treatment administered just once a month. That could be truly life-changing for these children and their families.

We’ve already generated the antibody and tested it to confirm that it doesn’t interfere with growth hormone signaling. We’ve also conducted studies in mice, where we demonstrated the expected accumulation of the target hormone. Our next major milestone is to evaluate the antibody in nonhuman primates, whose growth hormone biology is much more similar to that of humans. These studies will be an important step toward generating the preclinical evidence needed to advance the program toward clinical development and eventual regulatory approval. We’re currently raising funding to support this next phase.

Another exciting area of development for us is type 1 diabetes. I recently returned from a conference in Philadelphia focused on the disease, and we’re particularly enthusiastic about a novel treatment we’re developing with grant support from the Breakthrough T1D Foundation.

Our goal is to improve immunosuppression for children and adults who receive pancreatic islet cell transplants. These transplants have the potential to transform the lives of patients with type 1 diabetes by allowing them to produce their own insulin, significantly reducing or potentially eliminating their dependence on insulin injections.

However, there’s a major challenge. Because the transplanted cells come from a donor, the recipient’s immune system recognizes them as foreign tissue. Patients therefore require ongoing immunosuppression to prevent rejection. Unfortunately, current immunosuppressive regimens can be highly toxic, and some patients eventually have to discontinue treatment. When that happens, they risk rejecting the transplanted cells and losing the benefits of the procedure.

With our Eternabody platform, we’re working to develop a much more targeted approach to immunosuppression—one that is localized, effective, and significantly less toxic. Our hope is to protect the transplanted cells over the long term, allowing patients to maintain their insulin-producing grafts without the complications associated with conventional immunosuppressive therapies.

Ultimately, we want to help these patients preserve the benefits of transplantation for as long as possible, ideally for the rest of their lives. That’s another incredibly important program for us and a major focus of our next stage of development.

Having worked on both sides—as a scientist developing novel discoveries and as an entrepreneur evaluating their commercial potential—what are some of the most common mistakes you see researchers make when trying to translate their science into a biotech company?

I often see brilliant scientists become too attached to a particular target or hypothesis. As a scientist, you have to follow the data, and that becomes even more important when you’re trying to translate scientific discoveries into therapies.

One of the biggest mistakes is becoming so invested in a particular hypothesis that you spend years trying to prove it, even when the evidence suggests it may not lead anywhere. I’ve seen researchers publish 20 different papers on a single target without making meaningful progress toward a therapeutic application. But because they discovered it, believed in its potential, and invested so much time in it, they find it difficult to move on.

I think that mindset can be dangerous because it prevents scientists from pivoting, exploring new directions, and adapting quickly. In industry, particularly in biotech, you have to be agile. Funding is limited, the competitive landscape is constantly evolving, and unmet medical needs may be addressed by other companies before you get there. You need to recognize when something isn’t working and be willing to change direction rather than continuing to pursue an approach simply because you’ve invested years in it.

The other important lesson is recognizing that you can’t do everything yourself. Building the right team is absolutely critical. You may be an exceptional scientist, but that doesn’t necessarily mean you understand business development, drug development, or regulatory strategy. You need to surround yourself with people who bring complementary expertise and can help translate your scientific vision into a successful therapeutic program.

Those are probably the two biggest mistakes I see scientific founders make: becoming too attached to their original hypotheses and underestimating the importance of building a well-rounded team.

You founded Aeterna during a particularly challenging period for early-stage biotech financing. How have you approached fundraising and positioning the company to investors, and what have you learned about what today’s biotech investors are looking for?

Fundraising has certainly been challenging, especially as the biotech industry continues to recover from the post-COVID downturn. One thing that has helped tremendously is my decision to move from Canada to San Diego to launch the company. Everyone told me that San Diego was an incredible biotech hub for building connections, and they were absolutely right.

Since moving here, I’ve developed a strong network of colleagues, mentors, and friends who have been incredibly valuable throughout this journey. I’ve learned how to identify the right people to approach and leverage those relationships to secure warm introductions to venture capital firms. Building those connections has been one of the most important lessons for me as a founder.

I’ve also learned how to navigate the complex landscape of non-dilutive funding, including grants and other funding opportunities. It’s surprisingly difficult because many of these opportunities aren’t easily discoverable through a simple Google search. You really have to do your own research, build relationships, and create your own database of potential funding sources, which is exactly what I’ve done.

When it comes to venture capital, however, I think one of the biggest challenges is the shifting definition of what investors consider “too early.” In the past, being too early might have meant having only an idea or some preliminary in vitro data. Today, it sometimes feels as though you’re considered too early unless you’re already in the clinic. It’s somewhat ironic because many of these investors position themselves as early-stage or seed funds, yet they increasingly expect companies to have generated data approaching Phase 1 clinical development.

I think this creates a significant barrier for promising new biotech companies. There are brilliant scientific ideas with tremendous therapeutic potential that may never get off the ground simply because founders can’t secure the funding needed to advance them. The recent uncertainty surrounding government research funding has only compounded the problem, particularly for companies that depend heavily on grants and other non-dilutive sources of capital. Unfortunately, I’ve seen many talented scientists and entrepreneurs become so frustrated by these challenges that they ultimately give up.

There seems to be growing optimism that the funding environment is beginning to improve, and I certainly hope that’s the case. But I also believe we need to rethink how we support early-stage innovation. We can’t afford to let potentially transformative scientific discoveries disappear simply because they don’t yet meet increasingly demanding investment criteria. If we want to continue advancing medicine and developing breakthrough therapies, we have to create opportunities for promising ideas to receive the support they need at the earliest stages.